FDA Approves Vraylar (cariprazine) as an Adjunctive Treatment for MajorDepressive Disorder
December 16, 2022FDA Approves Tymlos as a Treatment to Increase Bone Density in Men withOsteoporosis at High Risk for Fracture
December 20, 2022December 19, 2022 - Eagle Pharmaceuticals, Inc announced today that the U.S. Food and Drug Administration has approved an additional indication for Pemfexy® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations. Eagle’s approved Pemfexy (pemetrexed injection) is a ready-to-dilute (“RTD”) novel liquid intravenous formulation developed to eliminate the reconstitution step of the Listed Drug (“LD”), ALIMTA®.